Cyclerion Therapeutics In... (CYCN)
NASDAQ: CYCN
· Real-Time Price · USD
2.39
0.06 (2.58%)
At close: Aug 15, 2025, 3:59 PM
2.39
0.00%
After-hours: Aug 15, 2025, 04:00 PM EDT
Cyclerion Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -1.95M | -2.94M | -3.06M | -5.28M | 3.01M | 149K | -5.26M | -10.79M | -28.85M | -38.05M | -44.08M | -47.64M | -48.43M | -51.23M | -51.65M | -60.1M | -67.62M | -70.97M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 65K | 65K | 82K | 130K | 113K | 161K | 262K | 472K | 894K | 1.43M | 1.93M |
Stock-Based Compensation | 488K | 558K | 625K | 606K | 627K | 822K | 1.07M | 2.09M | 3.59M | 4.91M | 6.25M | 7.67M | 8.43M | 9.07M | 9.61M | 10.27M | 11.65M | 13.27M |
Other Working Capital | 751K | 874K | 541K | 72K | -1.43M | -2.34M | -2.92M | -5M | -3.79M | -2.4M | -4M | 813K | 53.1M | 53.2M | 86.42M | 85.1M | 33.61M | 33.51M |
Other Non-Cash Items | -1.9M | -1.61M | -972K | -1.25M | -12.09M | -9.75M | -10.91M | -10.7M | 4.53M | 3.67M | 5.5M | 2M | -781K | 4.95M | 3.64M | -12.05M | -11.61M | -18.59M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.49M | -1.49M | -1.49M | -1.48M | 1K | 1K | 19.21M | 16.34M | 16.34M |
Change in Working Capital | 533K | 565K | -292K | 50K | -2.64M | -5.42M | -4.6M | -5.6M | -4.47M | -864K | -2.85M | 1.22M | 3.2M | 3.35M | 1.41M | -150K | 742K | 254K |
Operating Cash Flow | -2.83M | -3.43M | -4.33M | -6.23M | -11.45M | -16.9M | -21.25M | -26.75M | -29.73M | -33.99M | -40.61M | -42.2M | -40.21M | -34.9M | -36.52M | -41.93M | -49.05M | -57.77M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -7K | -14K | -14K | -14K | -42K | -44K | -119K |
Cash Acquisitions | n/a | n/a | n/a | -10.4M | n/a | n/a | n/a | 10.4M | n/a | n/a | n/a | n/a | n/a | 2K | 1.46M | 1.46M | 1.46M | 1.46M |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 7K | 7K | 9K | 1.47M | 2.94M | 2.95M | 2.96M |
Investing Cash Flow | n/a | n/a | n/a | -10.4M | n/a | n/a | n/a | 10.4M | n/a | n/a | n/a | -7K | -14K | -12K | 1.45M | 2.89M | 2.9M | 2.84M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 1.25M | 1.38M | n/a | 5.02M | 5.02M | 10.05M | 10.05M | 5.04M | 5.04M | 29K | 29K | 102K | 139K | 30.75M | 30.78M | 30.85M | 30.83M | 3.87M |
Financial Cash Flow | 1.25M | 1.38M | n/a | n/a | n/a | 5.02M | 5.02M | 5.04M | 5.04M | 29K | 29K | 102K | 145K | 30.76M | 30.79M | 30.86M | 55.08M | 28.12M |
Net Cash Flow | -1.58M | -2.06M | -4.34M | -6.24M | -1.05M | -1.47M | -5.81M | -11.3M | -24.68M | -33.96M | -40.58M | -42.1M | -40.07M | -4.14M | -4.27M | -8.17M | 8.94M | -26.82M |
Free Cash Flow | -2.83M | -3.43M | -4.33M | -6.23M | -11.45M | -16.9M | -21.25M | -26.75M | -29.73M | -33.99M | -40.61M | -42.2M | -40.22M | -34.91M | -36.53M | -41.97M | -49.1M | -57.88M |